Oncology Institute (NASDAQ:TOI) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Oncology Institute (NASDAQ:TOI - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06), Zacks reports. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The business had revenue of $100.27 million during the quarter, compared to the consensus estimate of $109.15 million. Oncology Institute updated its FY 2025 guidance to EPS.

Oncology Institute Trading Up 2.7 %

TOI stock traded up $0.03 during trading on Friday, hitting $1.14. The company had a trading volume of 502,477 shares, compared to its average volume of 700,965. Oncology Institute has a 52-week low of $0.13 and a 52-week high of $1.63. The company has a 50 day simple moving average of $0.86 and a 200-day simple moving average of $0.48. The firm has a market capitalization of $86.14 million, a P/E ratio of -1.46 and a beta of 0.41. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91.

Insider Buying and Selling at Oncology Institute

In other news, Director Mark L. Pacala acquired 90,562 shares of Oncology Institute stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of $1.04 per share, for a total transaction of $94,184.48. Following the acquisition, the director now directly owns 224,971 shares of the company's stock, valued at $233,969.84. This trade represents a 67.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased a total of 122,258 shares of company stock valued at $127,148 in the last three months. Company insiders own 9.50% of the company's stock.

Remove Ads

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.